Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015 The healthcare landscape is rapidly and ... & Sullivan will host its 20 th Anniversary ... March 8 to 10, at the Hilton San Diego Resort ... This event is a platform for global medical ... industry disruptions and how to succeed in an uncertain future. ...
(Date:2/26/2015)... PA (PRWEB) February 26, 2015 ... 9 -12, at the Ernest N. Morial Convention ... exhibitors (count as of February 19, 2015) displaying ... in industrial, academic, and government labs. The Exposition ... as, but not limited to, analytical chemistry; drug ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Innovation ... are emerging from unexpected parts of the world ... From agriculture to manufacturing to health care, ... and environmental realities and socio-political trends shake the ... the key ingredient for CEOs to survive the ...
(Date:2/26/2015)... According to a new market report ... Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled ... Growth, Trends and Forecast, 2013 – 2019,”the global agricultural ... 2012 and is expected to reach USD 28,694.1 million ... 2013 to 2019. , Demand for food production ...
Breaking Biology Technology:Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3
... ... ... ... ...
... ... Evonik for Industrial Biotechnology R&D Processes , ... Basel, Switzerland (PRWEB) February 23, 2010 -- ... announced an extended partnership with Evonik, a leading life science, specialty chemicals and ...
... Medicine , Susan Huang and colleagues describe the use ... by integrating two freely available software packages, to identify ... data from patients admitted to a 750-bed academic medical ... authors found that the tool identified a number of ...
Cached Biology Technology:Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 2Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 3Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 4Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 5Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 6Evonik Extends Long-term Research & Development Partnership with Genedata 2Evonik Extends Long-term Research & Development Partnership with Genedata 3Evonik Extends Long-term Research & Development Partnership with Genedata 4Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 2Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 3Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 4
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Mother Nature by developing, for the first time, ... tiny, hair-like structures through which organisms derive smell, ... new material isn,t exactly like cilia, it responds ... to control it and opening unlimited possibilities for ...
... BOSTONDana-Farber Cancer Institute,s Belfer Institute of Applied ... and NYSE: SNY) announced today that they have ... to identify and validate novel oncology targets ... novel therapeutics agents directed to such targets and ...
... Edward Yu of Iowa State University and the Ames Laboratory ... metal toxins from bacteria, making them resistant to antibiotics. ... of the journal Nature . Yu an ... of biochemistry, biophysics and molecular biology and an associate of ...
Cached Biology News:Cilia revolution 2Dana-Farber and sanofi-aventis establish cancer research alliance 2Iowa State, Ames Lab researchers identify structure that allows bacteria to resist drugs 2
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... FROM LIGHT. Useful in cell activation experiments when calcium ... TLC. Soluble in DMSO or EtOH. For ... stock in DMSO is recommended. Microliter amounts of this ... rapid mixing (e.g. 10 μl into 5 ml of ...
... poorly to Protein A and, until recently, no ... step IgM purification. Standard methods for IgM purification ... not effective for removing all of the major ... Pierce has developed an easy-to-use affinity ...
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... FROM MOISTURE. Protein synthesis inhibitor. Inhibits ... nascent polypeptide chains. Induces DNA fragmentation ... leukemia cells. Purity: ≥98% by ...
Biology Products: